Objective:

To contextualize the biological and clinical significance of hypoalbuminemia in MGUS, emphasizing its multifaceted role as a prognostic indicator and its implications for patient management.

Key Findings:

• Hypoalbuminemia (serum albumin ≤3.5 g/dL) is associated with increased risk of progression to multiple myeloma, highlighting its importance in clinical decision-making.
• Hypoalbuminemia reflects broader clinical phenotypes, including frailty and comorbidities, rather than solely plasma cell activity, indicating a need for comprehensive patient assessments.
• Systemic inflammation and host-related factors may significantly influence disease progression in MGUS, underscoring the complexity of patient management.

Interpretation:

Hypoalbuminemia serves as a composite surrogate for overlapping host-related mechanisms that may influence MGUS progression, highlighting the critical importance of integrating host biology into risk stratification.

Limitations:

• Retrospective, single-center design may introduce selection bias, potentially skewing results.
• Limited number of progression events in hypoalbuminemic subgroup leads to wide confidence intervals, affecting the reliability of risk estimates.
• Dependence on a single baseline albumin measurement does not capture dynamic changes, which may obscure true patient risk profiles.

Conclusion:

While hypoalbuminemia is a relevant prognostic indicator in MGUS, its interpretation should consider broader biological and clinical contexts, and further validation in diverse cohorts, including varying demographics and clinical settings, is necessary.